Fosun Pharma Subsidiary's Compound Polyethylene Glycol Electrolyte Powder Receives Registration Approval from National Medical Products Administration

Product / Tech
โดย Jiemian·Read original
Summary · why it matters

Fosun Pharma's controlled subsidiary Suzhou Erye Pharmaceutical has received registration approval from the National Medical Products Administration for its compound polyethylene glycol 3350 electrolyte powder. The drug specification is 6.9 grams per sachet, registered as a chemical drug category 3, indicated for the treatment of chronic constipation in children aged 1 to 11 years and fecal impaction in children aged 5 to 11 years. As of June 2026, cumulative research and development investment for this drug was approximately 2.62 million yuan.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

苏州二叶制药Private▲ Positive
Technologyrelevance

Company's drug approved for pediatric constipation treatment.

© 2026 MarketDXNews